obesity drug news today glp-1 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 Use of diabetes and anti-obesity

A., Holst, J

105 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Minority populations often face disproportionate challenges in insurance stability and coverage adequacy, which may translate into higher barriers to filling prescriptions despite potential financial assistance or discounts available to some groups

Hsu CN, et al

There are two types of GLP-1 drugs: short-acting GLP-1 drugs (e.g., Byetta or Victoza ) and newer long-acting GLP-1 drugs (e.g., Ozempic or Trulicity )

However, a significant and long-lasting reduction in body weight is difficult to achieve and various dietary regimens often fail both in the long term and in highly motivated patients